Rempex Pharmaceuticals, Inc., a development stage company, focuses on the discovery and development of antibacterial drugs. The company offers Minocin IV, a Minocycline for injection to wholesale pharmaceutical distributors in the United States. It is also developing RPX-602, a reformulation of Minocin IV; and Carbavance, an investigational agent that is a combination of a beta-lactamase inhibitor with a carbapenem. The company was founded in 2011 and is based in San Diego, California. As of December 3, 2013, Rempex Pharmaceuticals, Inc. operates as a subsidiary of The Medicines Company.